Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 2Phase 4 1

Status

Completed 4Terminated 2Unknown 1

Sponsor Class

OTHER 6NETWORK 1

Study Type

Interventional 7

Sponsor

Cancer Type

Plasma cell 7CNS 2Other hematologic neoplasm 1Lymphoid 1Gastrointestinal 1

Conditions

Multiple Myeloma 121Neoplasms, Plasma Cell 36Recurrence 7Immunoglobulin Light-chain Amyloidosis 5Renal Insufficiency 2Neoplasms 2Amyloidosis 2Urinary Bladder Neoplasms 1Urethral Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sarcoma, Kaposi 1Sarcoma 1Salivary Gland Neoplasms 1Renal Insufficiency, Chronic 1Rectal Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polyneuropathies 1Plasmacytoma 1Pinealoma 1Pathologic Complete Response 1Paraproteinemias 1Pancreatic Neoplasms 1Osteosarcoma 1Oligodendroglioma 1Neurotoxicity Syndromes 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroectodermal Tumors, Primitive 1Neuroblastoma 1

Interventions

Dexamethasone 109pomalidomide 52Cyclophosphamide 52Bortezomib 41fludarabine phosphate 33Lenalidomide 33Peripheral Blood Stem Cell Transplantation 28carfilzomib 26Mycophenolic Acid 25Calcium Dobesilate 24daratumumab 23Cyclosporine 22Busulfan 21Antilymphocyte Serum 20Tacrolimus 19Whole-Body Irradiation 18Melphalan 17Radiotherapy 15Filgrastim 15Methotrexate 14fludarabine 12Methylprednisolone 12elotuzumab 11Cord Blood Stem Cell Transplantation 11selinexor 10ixazomib 9Etoposide 8Thalidomide 7Prednisone 7Panobinostat 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Recurrence × Thalidomide × Plasma cell × Clear all
NCT00256776 2021-10-18

MMVAR - Velcade: Study of Velcade for the Treatment of Myeloma Patients After Autologous Transplantation

European Society for Blood and Marrow Transplantation

Phase 3 Terminated
269 enrolled 9 charts
Plasma cell

Multiple Myeloma, Recurrence

NCT01526694 2018-07-03

Phase II Trial Designed to Determine Efficacy and Safety of Bendamustine+Dexamethasone+Thalidomide in R/R MM

Azienda Ospedaliera di Bolzano

Phase 2 Completed
30 enrolled
Plasma cell

Multiple Myeloma, Recurrence

NCT03143036 2018-06-07

Daratumumab, Thalidomide and Dexamethasone in Relapse and/or Refractory Myeloma

National University Hospital, Singapore

Phase 2 Unknown
100 enrolled
Plasma cell

Recurrence, Neoplasms, Plasma Cell

NCT00538824 2018-06-06

DexTR

Weill Medical College of Cornell University

Phase 2 Terminated
5 enrolled 8 charts
Plasma cell

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT00652041 2011-09-19

TaCyDexVMP7

PETHEMA Foundation

Phase 4 Completed
40 enrolled
Plasma cell

Multiple Myeloma, Recurrence

NCT00602511 2011-02-09

Thalidomide Versus Bortezomib in Melphalan Refractory Myeloma

Nordic Myeloma Study Group

Phase 3 Completed
300 enrolled
Plasma cell

Multiple Myeloma, Recurrence

NCT00083681 2010-07-02

DCEP in Combination With Thalidomide as Salvage Therapy for Post Transplantation Relapse

University of Arkansas

Phase 2 Completed
180 enrolled
Plasma cell

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡